ZBIO Zenas Biopharma Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: ZBIO
  4. Earnings
Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 19

EPS in 2026 (TTM): -$9.62

Last Report Period Date: Jun 30, 2026

As of September 2026, ZBIO's current EPS stands at -$9.62, according to the latest financial reports. For the year 2025, the company recorded an earnings per share (EPS) of -$8.44, which marks an increase compared to its EPS of -$11.89 in 2024. ZBIO reported an EPS of -$1.77 for the quarterly report ending on Jun 30, 2026.

ZBIO earnings history

Historical annual and quarterly earnings per share (EPS) data for Zenas Biopharma
EPS (TTM)
-$9.62
EPS Growth YoY (Quarterly)
-41.6%
EPS (Quarterly)
-$1.77
EPS Growth (Quarterly)
-21.2%

For 2025, Zenas Biopharma's EPS was -$8.44, an increase of 29% from -$11.89 in 2024. For the fiscal quarter that ended on Jun 30, 2026, the per-share earnings was -$1.77, showing a 41.6% decrease from the same quarter last year. For the twelve months ending June 2026, the EPS is -$9.62. For the year 2024, the yearly earnings per share was -$11.89, marking an increase of 51% from 2023.

ZBIO EPS vs price chart

ZBIO EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-41.6%
EPS growth YoY
29%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

During the last 12 months, Zenas Biopharma has seen an EPS growth of -41.6% (YoY, quarterly).

ZBIO Earnings Waterfall

Breakdown of revenue, profit and net income for Zenas Biopharma

ZBIO Earnings vs Peers

What are the earnings of ZBIO compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
REGN Regeneron Pharmaceuticals Inc 19.12 5.3% 2.1% 5.7%
AMGN AMGEN Inc 25.04 88.1% 5.6% 2.9%
VRTX Vertex Pharmaceuticals Inc 29.79 843.3% 6% 8.2%
BIIB Biogen Inc 40.06 -21.2% -25% -18.7%
ALNY Alnylam Pharmaceuticals Inc 40.41 209.6% N/A N/A
ILMN Illumina Inc 47.29 171.1% N/A 4.1%
GILD Gilead Sciences Inc N/A 1,700% 23.2% 132.8%
MRNA Moderna Inc N/A 21.8% N/A N/A
SRPT Sarepta Therapeutics Inc N/A -388.7% N/A N/A
ZBIO Zenas Biopharma Inc. N/A 29% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.